-
公开(公告)号：US20130143905A1
公开(公告)日：2013-06-06
申请号：US13515852
申请日：2010-12-13
申请人： Heiner Ebel , Sara Frattini , Kai Gerlach , Riccardo Giovannini , Christoph Hoenke , Marco Santagostino , Stefan Scheuerer , Thomas Trieselmann
发明人： Heiner Ebel , Sara Frattini , Kai Gerlach , Riccardo Giovannini , Christoph Hoenke , Marco Santagostino , Stefan Scheuerer , Thomas Trieselmann
IPC分类号： C07D401/14 , C07D405/14
CPC分类号： C07D401/14 , C07D405/14
摘要： The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
摘要翻译： 本发明涉及式（I）的CCR2（CC趋化因子受体2）的新型拮抗剂及其用于治疗疾病，特别是肺疾病如哮喘和COPD的药物的用途。
-
12.发明申请New beta-agonists, processes for preparing them and their use as pharmaceutical compositions 有权新的β-激动剂，其制备方法及其作为药物组合物的用途公开(公告)号：US20060173061A1
公开(公告)日：2006-08-03
申请号：US11276649
申请日：2006-03-09
IPC分类号： A61K31/4178 , A61K31/4172
CPC分类号： C07D233/64 , C07D233/84 , C07D249/08 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12
摘要： The present invention relates to new beta-agonists of general formula 1: wherein the groups R1 to R12 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as pharmaceutical compositions.
摘要翻译： 本发明涉及通式1的新β-激动剂：其中R 1至R 12基团具有权利要求书和说明书中给出的含义，其异构体， 制备这些化合物的方法及其作为药物组合物的用途。
-
13.发明申请Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions 审中-公开β-激动剂，其制备方法及其作为药物组合物的用途公开(公告)号：US20050245526A1
公开(公告)日：2005-11-03
申请号：US11118295
申请日：2005-04-29
IPC分类号： C07D233/36 , C07D233/54 , C07D233/68 , C07D233/90 , C07D235/06 , C07D237/32 , C07D249/06 , C07D249/08 , C07D401/04 , C07D403/10 , C07D409/04 , C07D413/04 , A61K31/498 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/425 , C07D43/02 , C07D49/14
CPC分类号： C07D249/08 , C07D233/36 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/06 , C07D237/32 , C07D249/06 , C07D401/04 , C07D403/10 , C07D409/04 , C07D413/04
摘要： The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and their use as pharmaceutical compositions.
摘要翻译： 本发明涉及通式（I）的新的β-激动剂，其中基团R 1至R 7具有权利要求和说明书中给出的含义，互变异构体， 对映异构体，非对映异构体，其混合物，其前药及其盐，特别是其与无机或有机酸或碱的生理学上可接受的盐，制备这些化合物的方法及其作为药物组合物的用途。
-
14.发明申请Cyanothiophenes, their preparation and their use in pharmaceutical compositions 审中-公开氰噻吩，它们的制备及其在药物组合物中的应用公开(公告)号：US20060094764A1
公开(公告)日：2006-05-04
申请号：US11250018
申请日：2005-10-13
申请人： Ralf Anderskewitz , Gerd Morschhaeuser , Ruediger Streicher , Thomas Trieselmann , Rainer Walter
发明人： Ralf Anderskewitz , Gerd Morschhaeuser , Ruediger Streicher , Thomas Trieselmann , Rainer Walter
IPC分类号： A61K31/4436 , A61K31/381 , C07D333/38 , C07D409/02
CPC分类号： C07D333/38 , C07D409/12
摘要： The present invention relates to cyanothiophenes of general formula wherein the Rs are defined as in the claims, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly a glugacon receptor-antagonistic activity.
摘要翻译： 本发明涉及通式的氰基噻吩，其中Rs如权利要求中所定义，互变异构体，其立体异构体，其混合物及其盐具有有价值的药理学性质，特别是glugacon受体拮抗活性。
-
15.发明申请公开(公告)号：US20080269281A1
公开(公告)日：2008-10-30
申请号：US12091828
申请日：2006-10-27
IPC分类号： A61K31/437 , C07D471/04 , A61P3/10 , A61P3/04
CPC分类号： C07D471/04
摘要： Compounds of the formula which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylate and 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylic acid.
摘要翻译： 作为选择性β-3-激动剂并可用于治疗肥胖和II型糖尿病的式的化合物。 示例性化合物是：3- {3 - [（R）-2-（3-苯磺酰氨基 - 苯基）-2-羟基 - 乙基氨基] -3-甲基 - 丁基} -3H-咪唑并[4,5-b]吡啶 -5-羧酸乙酯和3- {3 - [（R）-2-（3-苯磺酰基氨基 - 苯基）-2-羟基 - 乙基氨基] -3-甲基 - 丁基} -3H-咪唑并[4,5-b]吡啶 -5-羧酸。
-
16.发明授权Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions 有权β-激动剂，其制备方法及其作为药物组合物的用途公开(公告)号：US07977334B2
公开(公告)日：2011-07-12
申请号：US12113780
申请日：2008-05-01
IPC分类号： A61K31/50 , C07D249/04
CPC分类号： C07D249/08 , C07D233/36 , C07D233/64 , C07D233/68 , C07D233/90 , C07D235/06 , C07D237/32 , C07D249/06 , C07D401/04 , C07D403/10 , C07D409/04 , C07D413/04
摘要： The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and their use as pharmaceutical compositions.
摘要翻译： 本发明涉及通式（I）的新β-激动剂，其中基团R 1至R 7具有权利要求和说明书中给出的含义，互变异构体，对映体，非对映体，其混合物，其前药和盐 特别是其与无机或有机酸或碱的生理上可接受的盐，制备这些化合物的方法及其作为药物组合物的用途。
-
17.发明申请CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD 审中-公开CYPIC PYRIMIDIN-4-CARBOXAMIDES作为CCR2受体拮抗剂用于治疗炎症，哮喘和COPD公开(公告)号：US20120053164A1
公开(公告)日：2012-03-01
申请号：US13140591
申请日：2009-12-17
申请人： Heiner Ebel , Sara Frattini , Riccardo Giovannini , Christoph Hoenke , Thomas Trieselmann , Patrick Tielmann , Stefan Scheuerer , Silke Hobbie , Frank Buettner
发明人： Heiner Ebel , Sara Frattini , Riccardo Giovannini , Christoph Hoenke , Thomas Trieselmann , Patrick Tielmann , Stefan Scheuerer , Silke Hobbie , Frank Buettner
IPC分类号： A61K31/506 , C07D405/14 , C07D413/14 , A61K31/5377 , C07D403/14 , A61K31/55 , C07D401/06 , C07D471/10 , C07D417/14 , C07D471/04 , C07D498/10 , C07D451/02 , A61K31/553 , C07D403/06 , A61K31/551 , A61P29/00 , A61P11/00 , A61P11/06 , A61P25/00 , A61P37/00 , A61P9/00 , A61P13/12 , A61P3/10 , A61P9/10 , A61P25/04 , C07D401/14
CPC分类号： C07D498/10 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/553 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/04 , C07D471/10 , C07D491/052 , Y02A50/385 , Y02A50/409 , Y02A50/411
摘要： The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, ═CH—, —CH2—, —O—, —S—, and —NH—; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.
摘要翻译： 本发明涉及CCR2（CC趋化因子受体2）的新型拮抗剂及其用于治疗疾病，特别是肺疾病如哮喘和COPD的药物的用途。 式（I）其中A选自单键，-CH =，-CH 2 - ， - O - ， - S - 和-NH-; 其中n为1,2或3; 其中Z是C或N，其它变量如权利要求中所定义，以及其与药理学上可接受的酸的酸加成盐的形式。
-
18.发明授权Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD 有权循环嘧啶-4-甲酰胺作为治疗炎症，哮喘和COPD的CCR2受体拮抗剂公开(公告)号：US08835440B2
公开(公告)日：2014-09-16
申请号：US13949696
申请日：2013-07-24
申请人： Heiner Ebel , Sara Frattini , Riccardo Giovannini , Christoph Hoenke , Thomas Trieselmann , Patrick Tielmann , Stefan Scheuerer , Silke Hobbie , Frank Buettner
发明人： Heiner Ebel , Sara Frattini , Riccardo Giovannini , Christoph Hoenke , Thomas Trieselmann , Patrick Tielmann , Stefan Scheuerer , Silke Hobbie , Frank Buettner
IPC分类号： A01N43/54 , C07D239/42 , C07D401/04 , C07D498/10 , C07D403/06 , A61K31/55 , C07D491/052 , C07D401/06 , A61K31/553 , C07D405/14 , C07D471/10 , C07D407/14 , C07D417/14 , A61K31/5377 , A61K31/551 , C07D471/04 , C07D403/14 , C07D451/02 , C07D401/14 , A61K31/506 , C07D413/14
CPC分类号： C07D498/10 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/553 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/04 , C07D471/10 , C07D491/052 , Y02A50/385 , Y02A50/409 , Y02A50/411
摘要： The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
摘要翻译： 本发明涉及CCR2（CC趋化因子受体2）的新型拮抗剂及其用于治疗疾病，特别是肺疾病如哮喘和COPD的药物的用途。
-
19.发明授权Beta-agonists, processes for preparing them and their use as pharmaceutical compositions 有权β-激动剂，制备它们的方法及其作为药物组合物的用途公开(公告)号：US07214698B2
公开(公告)日：2007-05-08
申请号：US11276649
申请日：2006-03-09
IPC分类号： A61K31/4164
CPC分类号： C07D233/64 , C07D233/84 , C07D249/08 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12
摘要： The present invention relates to new beta-agonists of general formula 1: wherein the groups R1 to R12 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as pharmaceutical compositions.
摘要翻译： 本发明涉及通式1的新β-激动剂：其中R 1至R 12基团具有权利要求书和说明书中给出的含义，其异构体， 制备这些化合物的方法及其作为药物组合物的用途。
-
![Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation](/abs-image/US/2015/10/06/US09150583B2/abs.jpg.150x150.jpg)
20.发明授权Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation 有权呋喃并[3,4-c]喹啉衍生物，含有这些化合物的药物，其用途和制备方法公开(公告)号：US09150583B2
公开(公告)日：2015-10-06
申请号：US13586977
申请日：2012-08-16
IPC分类号： C07D491/20 , A61K31/4747 , A61K45/06
CPC分类号： C07D491/20 , A61K31/4747 , A61K45/06
摘要： The present invention relates to compounds defined by formula I wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this protein.
摘要翻译： 本发明涉及由式I定义的化合物，其中变量R1-R8如描述中所定义，具有有价值的药理学活性。 特别地，化合物是胆固醇酯转移蛋白（CETP）的抑制剂，因此适用于治疗和预防可受该蛋白质抑制影响的疾病。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.052 秒)
